设为首页 电子邮箱 联系我们

本刊最新招聘信息请见“通知公告”!  本刊投稿系统试运行中,欢迎投稿!如投稿有问题,可直接将稿件发送至zgyy8888@163.com

 

主管单位:中华人民共和国   

国家卫生健康委员会

主办单位:中国医师协会
总编辑:
杨秋

编辑部主任:吴翔宇

邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)

                  

过刊目录

2021 年第 10 期 第 16 卷

丹参川芎嗪注射液联合血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体拮抗剂类药物治疗糖尿病肾病的系统评价

Systematic review on salvia miltiorrhizae and ligustrazine hydrochloride injection combined with angiotensin converting enzyme inhibitor/angiotensin Ⅱ receptor blocker drugs in the treatment of diabetic nephropathy

作者:王紫雯1荆鲁2李梓荣1杨俏丽1李金埕1覃锦1刘尚建1

英文作者:Wang Ziwen1 Jing Lu2 Li Zirong1 Yang Qiaoli1 Li Jincheng1 Qin Jin1 Liu Shangjian1

单位:1北京中医药大学东直门医院肾病内分泌科100700;2中国中医科学院眼科医院内科,北京100040

英文单位:1Department of Nephrology and Endocrinology Dongzhimen Hospital Beijing University of Chinese Medicine Beijing 100700 China; 2Department of Medicine Eye Hospital China Academy of Chinese Medical Sciences Beijing 100040 China

关键词:糖尿病肾病;丹参川芎嗪注射液;血管紧张素转换酶抑制剂;血管紧张素Ⅱ受体拮抗剂;系统评价

英文关键词:Diabeticnephropathy;Salviamiltiorrhizaeandligustrazinehydrochlorideinjection;Angiotensinconvertingenzymeinhibitor;Angiotensinreceptorblocker;Systematic 

  • 摘要:
  • 目的  系统评价丹参川芎嗪注射液联合血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体拮抗剂(ACEI/ARB)类药物治疗糖尿病肾病的有效性及安全性。方法检索中国知网、万方数据库、维普数据库、中国生物医学文献数据库、PubMedEmbaseCochrane Library、中国临床试验注册中心、ClinicalTrials.gov数据库,收集丹参川芎嗪注射液联合ACEI/ARB类药物治疗糖尿病肾病的随机对照试验,对照组采取基础治疗联合ACEI/ARB类药物治疗;观察组在对照组基础上加用丹参川芎嗪注射液治疗。检索范围为建库至20211月,采用RevMan 5.3软件进行Meta分析。结果 共纳入12篇随机对照试验。观察组干预糖尿病肾病的总有效率高于对照组,差异有统计学意义(相对危险度=1.2195%置信区间:1.131.29P0.001);观察组在改善患者血尿素氮、血肌酐、尿白蛋白排泄率等方面均优于对照组(均P0.05)。2组均未见严重不良反应。结论 丹参川芎嗪注射液联合ACEI/ARB类药物干预糖尿病肾病疗效较好,安全性较高。

  • Objective To systematically evaluate the efficacy and safety of salvia miltiorrhizae and ligustrazine hydrochloride injection combined with angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) drugs in the treatment of diabetic nephropathy (DN). Methods Randomized controlled trials (RCTs) of salvia miltiorrhizae and ligustrazine hydrochloride injection combined with ACEI/ARB drugs in the treatment of DN were retrieved from China National Knowledge Infrastructure, Wanfang database, China Science and Technology Journal database, China Biology Medicine disc, PubMed, Embase, Cochrane Library, Chinese Clinical Trial Registry and ClinicalTrials. gov database. The control group was treated with basic treatment combined with ACEI/ARB drugs, and the observation group was treated with salvia miltiorrhizae and ligustrazine hydrochloride injection on the basis of the control group. The search scope was from the construction of the databases to January 2021. RevMan 5.3 was used for Meta-analysis. Results A total of 12 RCTs were included in the study. The total effective rate of the observation group was higher than that of the control grouprisk ratio=1.2195% confidence interval:1.13-1.29P0.001. The observation group was better than the control group in improving blood urea nitrogen, blood creatinine and urinary albumin excretion rate (all P0.05). No serious adverse reactions were reported in both group. Conclusion Salvia miltiorrhizae and ligustrazine hydrochloride injection combined with ACEI/ARB drugs is effective and safe in the treatment of DN.

copyright 《中国医药》杂志编辑部
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址:www.chinamedicinej.com 京ICP备2020043099号-3

当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。







安卓


苹果

关闭